www.hivandhepatitis.com

Back HCV Treatment

Abbott and Enanta Announce First Clinical Trial of Oral HCV Protease Inhibitor ABT-450

Details
Category: Experimental HCV Drugs
Published on Friday, 20 February 2009 13:01
Written by Abbott & Enanta
  • Print

The current standard of care for treatment of chronic hepatitis C is combination therapy using pegylated interferon (Pegasys or PegIntron) plus ribavirin. The overall cure rate with this combination in HCV monoinfected patients with genotype 1 HCV is approximately 45%-50%. The success rate is higher for patients with genotype 2 or 3.

Read more:

Subcategories

Copyright © 2025 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design